News
Public · Published
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement — Barrons.com
Hims & Hers and Eli Lilly agreed to expand access to Lilly's Zepbound and Foundayo weight-loss medicines through Hims & Hers' consumer platform. Patients can consult a provider, receive a prescription if appropriate, and have FDA-approved treatment shipped home; stated monthly self-pay prices start at $149 for Foundayo and $299 for Zepbound.
Published:
Updated:
What happened
Hims & Hers and Eli Lilly agreed to expand access to Lilly’s Zepbound and Foundayo weight-loss medicines through Hims & Hers’ consumer platform. Patients can consult a provider, receive a prescription if appropriate, and have FDA-approved treatment shipped home; stated monthly self-pay prices start at $149 for Foundayo and $299 for Zepbound.
Confirmed
Global impact / market context
The arrangement links Lilly’s medicines with Hims & Hers’ online care and delivery channel. If prescriptions follow, wider access could support medicine sales for Lilly and bring more patients to Hims & Hers, while the stated self-pay prices may shape demand and revenue per patient.
Analyst inference
The article describes Hims & Hers shares as down 26% this year and 37% from their July 6 close, while reporting a 6.8% premarket rise to $25.70 on Friday after the agreement. It presents the deal as a positive development following recent share weakness.
Confirmed
What to watch
- Watch whether patients complete consultations and receive prescriptions; the agreement allows a provider to prescribe Lilly treatment only when the provider considers it appropriate. Analyst inference
- Track whether the companies disclose changes to access, delivery, or the stated self-pay prices of $149 monthly for Foundayo and $299 for Zepbound. Analyst inference
- The article says Hims & Hers has never offered “ac…” before its text cuts off, so it does not establish what products or services were previously excluded. Confirmed
Evidence
- Original source link unavailable